Navigation Links
Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
Date:1/30/2008

IRVING, Texas, Jan. 30 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) said it retained Milkie/Ferguson Investments, Inc. as its financial advisor to assist it in exploring a range of financial alternatives.

"Our hiring of a financial advisor is a continuation of our efforts to thoroughly consider our business model and all opportunities going forward," said Carlton Turner, PhD, chief executive officer of Carrington. "We have valuable technologies and assets which we believe have significant emerging potential and we look forward to working with Milkie/Ferguson on these initiatives."

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) polymer technology designed to provide controlled release of peptide and protein-based drugs. A second technology Gelvac(TM) is designed for dry powder nasal delivery of vaccines without the need for preservatives, adjuvants, cold storage and shipping under cold conditions. One influenza vaccine, (H1N1 antigen) with this technology, has been stable for more than three years at room temperature.

Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

About Milkie/Ferguson

Milkie/Ferguson Investments is a full-service, FINRA- and SIPC-member broker-dealer and boutique investment bank specializing in financing, fairness opinions, valuations, mergers and acquisitions. Milkie/Ferguson is distinguished by putting the client's interest first, providing senior-level attention, maximizing client value, and providing the premium level of service of top-tier investment banks. Milkie/Ferguson draws on its broad foundation and experience to create a tailored approach for each client that results in success. Among the firm's more recent engagements was as advisor to Reddy Ice Holdings, Inc on the $20 million sale of businesses unrelated to its bagged- ice focus.

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.

For Information Contact:

Robert Schnitzius, Chief Financial Officer

(972) 518-1300


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Reports Third Quarter 2007 Results
2. Carrington Reports on ISO 9001:2000 Inspection
3. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
4. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
7. Carrington Completes $8 Million Financing
8. Carrington Reports Second Quarter 2007 Results
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
11. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):